Ceperognastat did not slow clinical progression in an Alzheimer’s trial

On this page

Study design

This double-blind phase 2 trial randomized 327 people with early symptomatic Alzheimer’s disease to once-daily ceperognastat at 0.75 mg, 3 mg, or placebo. The primary analysis focused on participants with low-to-medium tau PET burden and tracked the Integrated Alzheimer Disease Rating Scale for 100 weeks.

What it found

The drug did not meet the study’s criterion for slowing clinical progression, and no benefit appeared on secondary clinical outcomes. Modelled decline was smaller with 0.75 mg than placebo, while the 3 mg group declined more. Neither result established a meaningful clinical benefit; serious adverse events were more frequent at the higher dose.

Limits and interpretation

This company-affiliated phase 2 trial used a biomarker-defined primary population and model-based success threshold. A PET biomarker change in one region did not translate into demonstrated clinical improvement. The result applies to this molecule, doses, population, and follow-up; it does not settle every approach to tau biology.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

• Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial — JAMA · 13 July 2026

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news